Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Cannabis Policy topic
No spam. Unsubscribe anytime.
Cannabis Control Board tells panel medical program is shrinking; proposes Canify tool, vape safeguards and a review process for qualifying conditions
Summary
The Cannabis Control Board reported falling medical patient numbers, recommended a vetted decision tool (Canify) for point‑of‑sale guidance, flagged vape cartridge contaminants and battery disposal as concerns, and raised whether qualifying condition review should move outside the Legislature.
The Cannabis Control Board told the House Human Services Committee on Oct. 12 that Vermont’s medical cannabis program has many services not available under adult use but that patient enrollment has fallen since home cultivation and adult‑use legalization, prompting questions about how to preserve medical protections and whether the state should change who decides qualifying conditions.
"There is kind of an inherent dissonance with the medical program, because cannabis is a controlled... schedule 1 controlled substance federally," James Pepper, chair of the Cannabis Control Board, told the committee. Pepper reviewed an Act 166‑required report that documented declining patient registrations, consolidation of standalone medical dispensaries and the emergence of co‑located adult‑use/medical retail sites.
Board members said the medical program still offers services not available in adult use — such as tax exemptions, higher possession limits, caregiver registrations, home‑delivery and certain custom formulations — and that preserving access for qualifying patients is a stated goal. Pepper described a proposed decision‑support tool, Canify, developed by an academic team to provide evidence‑based guidance at the point of sale and during patient self‑assessment. "This might be a useful tool in the toolbox," Pepper said, noting the Department of Health would vet messaging and that product‑matching features slated for the vendor’s free version would be removed for Vermont use.
The board flagged product safety concerns for inhalation devices: regulators in other jurisdictions have found heavy metals and other contaminants in some vape cartridges, and federal Schedule I status and a limited research base complicate clinical guidance. Pepper said other jurisdictions, such as New Jersey, have set maximum heating/voltage limits for cartridges; the board recommended aligning any device restrictions with an upcoming state battery stewardship program because many vape devices contain non‑removable lithium‑ion batteries.
The report also addressed the recurring policy question of who should evaluate and add qualifying medical conditions. Pepper summarized options: keep legislative control, create a Department of Health petition/review process (used in several other states) or authorize the Cannabis Control Board to add conditions by rule. Committee members noted medical evidence is limited by Schedule I restrictions and that adding broadly defined conditions (for example, anxiety or chronic pain) has substantial fiscal and program implications.
The board recommended several next steps: deploy an education and decision‑support strategy (including a vetted Canify instance and a tailored staff training requirement for medical endorsements), coordinate with the Department of Health on public health messaging, monitor devices and battery stewardship developments, and consider establishing a non‑legislative review mechanism for qualifying conditions if the Legislature directs it. The committee did not adopt policy changes at the hearing and asked the board to provide additional cost and implementation details if the Legislature wishes to pursue changes next year.
